https://www.selleckchem.com/products/apcin.html
Local control will be defined according to the Response Assessment in Neuro-Oncology (RANO) criteria. Discussion This study is the first prospective trial to investigate the safety of dose-reduced SRS in treatment of brain metastases with concomitant ICI. The findings should provide fertile soil for future multi-institutional collaborative efficacy trials of RADREMI dosing for this patient population. Trial registration Clinicaltrials.gov identifier NCT04047602 (registration date July 25, 2019).Aim The purpose of this study was to evaluat
Like
Comment
Share
